other material
confidence high
sentiment positive
materiality 0.75
Armata delays Q4/FY2025 earnings; FDA grants QIDP for phage candidate AP-SA02
Armata Pharmaceuticals, Inc.
- Will delay Q4/FY2025 financial results announcement; expects to file 10-K by March 31, 2026 due date.
- FDA granted QIDP for AP-SA02 (S. aureus phage) as adjunct treatment for complicated bacteremia, adding Hatch-Waxman exclusivity.
- FDA alignment reached on Phase 3 superiority study design; Armata plans to initiate study in H2 2026.
- cGMP manufacturing facility in Los Angeles (~56,000 sq ft) formally commissioned; full production runs completed.
- Phase 2a diSArm study showed higher cure rates with AP-SA02 plus antibiotics vs antibiotics alone; results presented at IDWeek 2025.